NAMES OF COMPANIES ADDRESS PHONE NUMBER

GenVec, Inc. 65 West Watkins Mill Road (240) 632-0740

Kirkegaard and Perry Laboratories, Inc. 910 Clopper Road (301) 948-7755
Science Applications International 5340
Corp.Spectrum
(SAIC) Dr., Frederick MD 21703-7365 3016986188
Bioscience Super Array 7320 Executive Way, Frederick, MD 21704 (301) 682-9200
GeneDx 207 Perry Parkway (301) 519-2100
MiddleBrook Pharmaceuticals 20425 Seneca Meadows Parkway (301) 944-6600
Tetracore, Inc. 9901 Belward Campus Drive (240) 268-5400
NABI Biopharmaceuticals 12276 Wilkins Avenue (301) 770-3099
EntreMed, Inc. 9640 Medical Center Drive (240) 864-2660
Avalon Pharmaceuticals, Inc. 20358 Seneca Meadows Parkway (301) 556-9900
Vanda Pharmaceuticals Inc. 9605 Medical Center Drive (240) 599-4500
BIOQUAL (3) 9600 Medical Center Drive (301) 251-2801
Emergent BioSolutions Inc 2273 Research Boulevard (301) 795-1800
Pharmaceutical Preparation Mfg United Therapeutics 1110 Spring St., Silver Spring, MD 20910-4019 (301) 608-9292
SGS Life Science Services - Clinical Research 12850 Middlebrook Road (877) 677-2667
Quality Biological, Inc. 7581 Lindbergh Drive (301) 840-9331
Functional Genetics 708 Quince Orchard Road (240) 631-6790
Appropriate Technical Resources, Inc. P.O. Box 460 (301) 470-1267
Sensors for Medicine and Science, Inc. 20451 Seneca meadows Parkway (301) 515-7260
Sanofi-Aventis 801 Pennsylvania Ave. NW, D.C. (202) 682-0538
BioServe 9000 Virginia Manor Road (301) 470-3362
Cato Research 9605 Medical Center Drive (301) 309-1260
Bioscience International, Inc. 11333 Woodglen Drive (301) 231-7400
Qiagen Sciences, Inc. (3 in Gaithersburg) 19300 Germantown Road (240) 686-7300
Amaxa, Inc 205 Perry Parkway (240) 632-9110
Trevigen 8405 Helgerman Ct., Gaithersburg, MD 20877-4131 (301) 560-4973
Accelovance Suite 7 (240) 238-4900
GlycoMimetics, Inc. Gaithersburg, MD 20877 (240) 243-1201
Cytomedix, Inc. 416 Hungerford Drive (240) 499-2680
Transgenomic 11 Firstfield Rd # C, Gaithersburg, MD 20878-1704 (240) 631-2001
Calibrant Biosystems, Inc. 910 Clopper Road (301) 977-7900
Alfagene Bioscience Inc. 201 Perry Pkwy, Gaithersburg, MD 20877
BIOCON, Inc. (2; Gaithersburg branch as well) 649 A Lofstrand Lane (301) 762-3202
ExonHit Therapeutics, Inc. 217 Perry Parkway (240) 683-7070
Applied Cell Sciences, Inc. 9430 Key West Avenue (240) 453-6331
Ani Lytics, Inc. 200 Girard Street (301) 921-0168
The EMMES Corporation 401 North Washington Street (301) 251-1161
Theranostics Health 15010 Broschart Rd (301) 251-4443
BioFactura, Inc. 9700 Great Seneca Highway (301) 315-8002
Lab Products, Inc. 11300 Rockville Pike (301) 468-0250
AscentGene, Inc. 387 Technology Drive (240) 899-6538
BioFortis Inc. 9017 Red Branch Rd 1 to 4
Bacilligen, Inc. 9700 Great Seneca Highway (301) 217-9525
Drug Development SVC Summit 15204 Omega Drive (240) 361-9105 1
Doe & Ingalls of Maryland, LLC 8220 Patuxent Range Road (919) 598-1986
CoGenesys, Inc. 9410 Key West Avenue (240) 821-9000
Creatv MicroTech, Inc 11609 Lake Potomac Drive (301) 983-1650
Correlogic Systems, Inc. (2; bethesda) 1405 Research Blvd (301) 795-1700
20/20 GeneSystems, Inc. 9430 Key West Ave (240) 453-6339
 Adlyfe, Inc. (301) 424-8344
Fisher BioServices 14665 Rothgeb Drive (301) 315-8460
Otsuka America Pharmaceutical, Inc. (2 branches) 2440 Research Blvd. (301) 990-0030
Protein Society9650 Rockville Pike, Bethesda, MD 20814-3999 (301) 634-7240
KamTek, Inc. 7858 Beechcraft Avenue (301) 208-2505
RNL Biostar, Inc. 9700 Great Seneca Hwy (240) 453-9393
Pharmacies & Drug Stores Amethyst Technologies Laurel, MD 20707-0000 (301)776-8461
G-MED North America, Inc. 8070 Georgia Avenue (301) 495-0477
Advanced Biomimetic Sensors, Inc 12111 Parklawn Drive (301) 881-8174
Advanced Genomics Technology Center (AGTC) 3007 Williams Drive (866) 599-2482
Advanced Product Enterprises LLC 4539 Metropolitan Court (301) 644-3913
Alba Therapeutics, Inc 800 West Baltimore Street (410) 319-0780
Amarex Clinical Resevarch, LLC 20201 Century Boulevard (301) 528-7000
Amulet Pharmaceutical, Inc. 9430 Key West Avenue (240) 499-2742
Arcion Therapeutics Inc 2400 Boston St (301) 325-3718
BIOMERE LLC 7939 Sandalfoot Drive (301) 365-2493
Germantown, MD 20876
TraumaCure, Inc. 7735 Old Georgetown Road (240) 497-0910
12th Floor
American Red Cross 15601 Crabbs Branch Way (301) 738-0575

VIRxSYS Corporation 200 Perry Parkway (301) 987-0480

Suite 1A
STB Lifesaving Technologies, Inc. 15601 Crabbs Branch Way (301) 738-0424
Rockville, MD 20855
Weinberg Medical Physics 5611 Roosevelt Street (301) 346-7944
Bethesda, MD 20814
Tsumura USA Inc 1700 Rockville Pike (301) 468-1030
Suite 360
Sirnaomics, Inc 401 Professional Drive (301) 977-6553
Blue Torch Medical Technology 9700 Great Seneca Highway (508) 231-1080
Global Research Services, LLC (GRS) 2101 Gaither Rd. (301) 296-4742
Suite 450
Global Drug Development Experts 910 17th Street, NW (202) 887-1690
Suite 312
Individual Health Solutions, LLC 8323 Sharon Drive (301) 874-1797
Suite 100
Innovative Biosensors, Inc. 15601 Crabbs Branch Way (301) 738-0604
Rockville, MD 20855
Integrated BioTherapeutics Inc. 4539 Metropolitan Ct (301) 644-3919
Frederick, MD 21704
DP Clinical, Inc. 1803 Research Boulevard (301) 294-6226
Suite 404
Clarassance, Inc. 9700 Great Seneca Highway (301) 452-2899
Suite 265
Cytimmune Sciences, Inc. 9640 Medical Center Drive (240) 864-2796
Rockville, MD 20850
Foundation for The National Institutes of Health (FNIH) 9650 Rockville Pike (301) 443-1609
Building 5
UMBI (Center for Advanced Research in Biotechnology) 9600 Gudelsky Drive (240) 314-6119
Rockville, MD 20850
 Panacea Pharmaceuticals, Inc. 207 Perry Parkway (240) 243-8000
Suite 2
Mosaigen 9700 Great Seneca Highway (301) 792-4345
Rockville, MD 20850
Neuralstem, Inc. 9700 Great Seneca Highway (301) 633-7709
Rockville, MD 20850
Paragen, Inc. 1833 Baltimore Street, NW (202) 421-6892
Gaithersburg, MD 208795412
QRxPharma Ltd. 155 Gibbs Street (301) 908-3086
Suite 510
RAPID Laboratories, Inc. 15601 Crabbs Branch Way (301) 738-0772
Rockville, MD 20855
Protein Potential, LLC 9800 Medical Center Dr STE A209 (301)-770-5554
Rockville, MD 20850
PlantVax, Inc 9700 Great Seneca Highway (240) 453-6247
Suite 182
MedImmune, Inc. (8 in MD; 1 in DC) One MedImmune Way (301) 398-0000
Gaithersburg, MD 20878
MaxCyte, Inc. 22 Firstfield Road (301) 944-1700
Suite 250
Global Drug Development Experts 910 17th Street, NW (202) 887-1690
Gaithersburg, MD 20878
Keygene, Inc. Rockville Innovation Center, 155 Gibbs Street (240) 205-7083
Suite 405
KAI Research, Inc. 6001 Montrose Road (301) 770-2730
Suite 920
Gaithersburg, MD 20879
WEBSITE NUMBER OF STAFF
http://www.genvec.com 109
http://www.kpl.com 80
http://www.saic.com 70
www.superarray.com 70
http://www.genedx.com 70
http://www.MiddleBrookPharma.com 67
http://www.tetracore.com 65
http://www.nabi.com 60
http://www.entremed.com 57
http://www.avalonrx.com/ 56
http://www.vandapharm.com 50
http://www.bioqual.com 50
http://www.emergentbiosolutions.com 49
http://www.unither.com/UnitherHome.aspx 30
http://www.sgs.com/lifescience 25
http://www.qualitybiological.com 25
http://www.functional-genetics.com 24
http://www.atrbiotech.com 20
http://www.s4ms.com 20
http://www.sanofi-aventis.us 20
http://www.bioserve.com/ 20
http://www.cato.com 20
http://www.biosci-intl.com 19
http://www.qiagensciences.com 19
http://www.amaxa.com 17
www.trevigen.com 17
http://www.accelovance.com/index.htm 16
http://www.glycomimetics.com 13
http://www.cytomedix.com/ 11
www.transgenomic.com 11
http://www.calibrant.com 10
http://www.alfagene.com/ 9
http://www.bioconinc.com 9
http://www.exonhit.com 9
http://www.appliedcellsci.com 9
http://www.latanet.com/e-source/!VENDORS.AD/!ANILYTI.HTM 7
http://pub.emmes.com 7
http://www.theranosticshealth.com/ 5
http://www.biofactura.com 5
http://www.labproductsinc.com 5
http://www.ascentgene.com/ 5
http://www.biofortis.com 4
http://www.bacilligen.com/home.aspx 4
http://www.summitdrug.com 4
http://www.doeingalls.com 4
http://www.cogenesys.com 4
http://www.creatvmicrotech.com 4
http://www.correlogic.com 4
http://www.2020gene.com 4
http://www.adlyfe.com 4
http://www.fisherbioservices.com 4
http://www.otsuka.com 4
http://www.proteinsociety.org/ 4
http://www.kamtekinc.com 4
http://www.rnlbiostar.com 4
http://www.amethysttech.com/news.htm 4
http://www.gmed.fr/index_en.asp 3

http://www.agtcenter.com
http://www.ape-bio.com
http://www.albatherapeutics.com
http://www.amarexcro.com
http://www.amuletpharma.com

http://www.biomere.com

http://www.traumacure.com

http://www.redcross.org

http://www.virxsys.com

http://www.stbbandage.com

http://www.tsumura.co.jp

http://www.sirnaomics.com
http://www.bluetorchmed.com/
http://www.grs-cro.com

http://www.gddexperts.com

http://www.signaturesupplements.com

http://www.innovativebiosensors.com

http://www.ibtinc-usa.com

http://www.dpclinical.com

http://www.clarassance.com

http://www.cytimmune.com

http://www.fnih.org

http://www.umbi.umd.edu
http://www.panaceapharma.com

http://www.mosaigen.com

http://www.neuralstem.com

http://www.para-gen.com/

http://www.qrxpharma.com

http://www.rapidpharma.com

http://www.proteinpotential.com

http://www.medimmune.com

http://www.maxcyte.com

http://www.gddexperts.com

http://www.keygene.com

http://www.kai-research.com
 ANNUAL SALES EMAIL DESCRIPTION OF INDUSTRY
$18,923,000 mtucker@genvec.com GenVec is an emerging biopharmaceutical company developing gene-based
$20 to 50 million Businessdevelopment@kpl.com
KPL is a supplier of reagents and kits (i.e. complete systems) used for detect
10 to 20 million SAIC provides technical and analytical contract support for biomedical produ
$20 to 50 million
$10 to 20 million genedx@genedx.com GeneDx provides rapid molecular diagnosis of rare hereditary disorders, serv
$16,848,000 MiddleBrook Pharmaceuticals is a therapeutically-focused biopharmaceutica
$20 to 50 million Tetracore is a biotechnology R&D and product company whose mission is to
$20 to 50 million mkalnik@nabi.com (Matthew NabiKalnik,
is developing
Ph.D.) breakthrough anti-infective products, vaccines and specifi
$6,894,000 tomb@entremed.com (Thomas EntreMed,
Bliss)Inc. (Nasdaq: ENMD) is a clinical-stage pharmaceutical company
$2,724,000 A research and development company focusing on developing theraputic trea
$80,038,000 IT exe.: Gunther Birznieks
$21,869,000 BIOQUAL has commercial and government contracts providing holding and t
$20 to 50 million (note: website looks like search
Emergent
engine)
BioSolutions Inc. is a biopharmaceutical company dedicated to on
$210,943,000 webmaster@unither.com IT Exec.: Mr. Shola Oyewole
SGS' Life Science Services has 30 years of experience as a global contract s
$10 to 20 million info@qualitybiological.com Quality Biological manufacturers and sells biological reagents and cell culture
info@functional-genetics.com
Funtional Genetics Inc. is a growing biotechnology comapny which is a privat
10 to 20 million Appropriate Technical Resources, Inc. has been serving the scientific researc
2.5 to 5 million Sensors for Medicine and Science provides sensing technologies for the dete
2.5 to 5 million With 2006 net sales of 28.4 billion euros and an estimated 100,000 employee
10 to 20 million info@bioserve.com BioServe is a leader in the processing, development, and validation of diagno
2.5 to 5 million info@cato.com Cato Research is an independent, full-service contract research and develop
Bioscience International, Inc. provides microbiologists with microbial air samp
$500,000 (note: prb logging on website)
Qiagen is the world's leading provider of innovative enabling technologies for
2.5 to 5 million (note: email forms on website)
A biotech firm located in Gaithersburg, MD specializing in gene transfer techn
$5 to 10 million info@trevigen.com
2.5 to 5 million info@accelovance.com
webmaster@glycomimetics.comGlycoMimetics is a biotechnology company developing novel therapautics ba
$1,943,000 info@cytomedix.com Cytomedix, Inc. is a biotechnology company specializing in processes and pr
$5 to 10 million info@transgenomic.com
Calibrant Biosystems is pioneering the discovery of novel proteins targets an
info@alfagene.com
bioconinfo@bioconinc.com BIOCON, Inc. is a research laboratory servicing the biomedical and biotechn
ExonHit Therapeutics is the world’s leader in the analysis of alternative RNA
Discover and validate novel drug-discovery targets, with particular emphasis
Ani Lytics, Inc. performs hematologic and clinical chemistry testing, custom m
$500,000 to 1 million webmaster@emmes.comThe EMMES Corporation is a contract research organization (CRO) providing
info2@theranosticshealth.com
Headquartered in Rockville, Maryland, THX is a start-up life science Compan
$1 to 2.5 million BioFactura is committed to bringing innovative science, advanced process te
$1 to 2.5 million Lab Products is the leading manufacturer of quality products for the biomedic
info@ascentgene.com AscentGene, Inc. is a developing stage biotechnology company that uses its

Bacilligen is an NIH-funded Maryland corporation whose primary focus is the

5 to 10 million Summit Drug Development, LLC, offers comprehensive drug development se
$500,000 to 1 million Doe & Ingalls of Maryland is a chemical service provider who helps biotechno
$ 5 to 10 million
Creatv MicroTech develops diagnostic instruments, devices and research too
$ 5 to 10 million Correlogic Systems, Inc. has pioneered the use of pattern recognition techno
20/20 GeneSystems, Inc. is a biotechnology company that has developed an
 Adlyfe, Inc. is a new biotechnology company founded in the spring of 2003 to
$1 to 2.5 million Info.FisherBioServices@Thermofisher.com
Fisher BioServices provides biomedical services including storage
$500, 000 to 1 million webmaster@otsuka.com Otsuka's roots date back to 1921, when Busaburo Otsuka founded the origin
cyablonski@proteinsociety.org
$500,000 to 1 million kamtekinc@aol.com KamTek promotes investigations in systems biology by offering Genomics, P

$500,000 to 1 million
$500,000 to 1 million gmedna@lne-gmed.com

Advance Genomics is a biotechnology company organized in 2007 to addres

Alba Therapeutics Corporation is a clinical stage biopharmaceutical company

Amulet Pharmaceuticals, Inc is an early stage biotechnology company develo

Arcion Therapeutics Inc. is a clinical stage biotechnology company focused o
BIOMERE LLC solves a critical need of biotech companies by providing acce

Housed in the Jerome H. Holland Laboratory for the Biomedical Sciences in R

VIRxSYS Corporation is an early-stage biotechnology company developing p

inweinberg@gmail.com STB Lifesaving Technologies, Inc. was founded to support the research, dev

WMP's staff previously started two companies in molecular breast imaging. W

info-office@sirnaomics.com

info@grs-cro.com

Global Research Services (GRS) is a full-service clinical trials management o

gsandman@signaturesupplements.com
Global Drug Development Experts specializes in partnering with Pharmaceut

Individualized nutrition analysis and nutrition solution.

DP Clinical (DPC) is a full service contract research organization (CRO) loca

(note: email forms on website)

Clarassance is a privately held Delaware Corporation formed exclusively to d

(note: email forms on website)

CytImmune is focused on developing colloidal gold as a targeted drug/gene d

foundation@fnih.org The Foundation for the National Institutes of Health supports the mission of th

The Center for Advanced Research in Biotechnology (CARB) is a research c

(note: new website; 'coming
Panacea
soon') Pharmaceuticls, Inc. is a privately-held biopharmaceutical company

irgarr@neuralstem.net (Richard Garr)

irgarr@neuralstem.net Neuralstem is a biotechnology company focused on developing and commer

(note: goto website for email form)

(note: goto website for email

QRxPharma
form) is a late-stage specialty pharmaceutical company with reposition

RAPID Laboratories, Inc. is a drug discovery and development company who

Protein Potential provides pharmaceutical and biotechnology companies, and

infobusdev@medimmune.com
ProCell Corporation, was founded in 2000 to develop and commercialize disc

info@maxcyte.com MedImmune strives to provide better medicines to patients, new medical opt

info@gddexperts.com MaxCyte is a clinical-stage cell therapeutics company with rapidly growing pi

info@gddexperts.com Global Drug Development Experts specializes in partnering with Pharmaceut

kai@kai-research.com Keygene develops and applies novel technologies in the field of molecular ge

KAI's staff of over 70 full time employees includes senior project managers, p
pany developing gene-based medicines for the treatment of major diseases, such as cancer and cardiovascular disease. GenVec uses gen
ete systems) used for detection of proteins and nucleic acids across a wide spectrum of assay platforms including ELISA, western, Northern
upport for biomedical product development. Their operations contain biomedical scientists, chemists, biomedical engineers, cost analysts, d

re hereditary disorders, serving the clinical needs of patients, physicians genetic counselors and researchers worldwide. We offer mutation
y-focused biopharmaceutical company, developing novel therapeutics for infectious diseases.
ompany whose mission is to create and develop highly innovative diagnostic reagents and assays for infectious diseases and bio-terrorism t
oducts, vaccines and specific polyclonal antibodies to address life-threatening bacterial and viral diseases and their associated complication
ge pharmaceutical company developing a new generation of multi-mechanism drugs for the treatment of cancer and inflammatory diseases
on developing theraputic treatments for cancer through genomics.

racts providing holding and technical services using animal models ranging from mice to non-human primates. Applications include breeding
al company dedicated to one simple mission�to protect life. The company develops, manufactures and commercializes immuno

erience as a global contract service organization providing integrated solutions from preclinical activities to Phase I-IV trials, bioanalytical and
ical reagents and cell culture media. They also provide facilities management and contract support to government and private institutions.
gy comapny which is a privately held firm focused on developing level novel drugs for infectious diseases including: Influenza, HIV, Ebola, a
serving the scientific research community for over 25 years in sales, service, and manufacturing. ATR currently manufactures the hybridizat
ing technologies for the detection and measurement of molecules of significant commercial interest. The Company's lead product developm
estimated 100,000 employees worldwide, sanofi-aventis is one of the world's largest pharmaceutical companies. Global headquarters are lo
ment, and validation of diagnostic tests for the practice of personalized, predictive and preventive medicine. Leading pharma, biotech and dia
ntract research and development organization with international resources dedicated to helping pharmaceutical and biotechnology compani
ogists with microbial air samplers, automated medium preparation equipment, autoclaves, environmental monitoring tools and NIST traceabl
ve enabling technologies for the purification and handling of DNA and RNA.
alizing in gene transfer technology.

loping novel therapautics based on glycobiology. Our focus is on inflammation and infectious disease.
cializing in processes and products derived from autologous platelet releasates for use on wounds and other applications. The current offeri

of novel proteins targets and biomarkers for the treatment of cancer. Calibrant's uniquely targeted approach to biomarker discovery is base

he biomedical and biotechnology communities and specializing in animal related services and equipped to provide all phases of animal rese
analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases. ExonHit has a mu
ts, with particular emphasis on GPCR targets. Also supplies a variety of products and services (such as large-scale cell culture and large-sc
chemistry testing, custom method development, and consultation supporting biomedical research.
organization (CRO) providing biostatistical and epidemiological project management and support, as well as organizational and logistical su
start-up life science Company with a singular focus: enabling the promise of personalized therapy to become a reality. Theranostics is the ab
cience, advanced process technology, and total quality services to the pioneers of biologic medicine. We offer a broad range of process dev
ity products for the biomedical research community. Products include an extensive line of equipment for the housing of laboratory animals a
ology company that uses its proprietary innovative technologies to develop, manufacture, and market a new generation of diagnostic device

n whose primary focus is the development of vaccine platform technologies for AIDS and biodefense/emergency preparedness. The compan
ensive drug development services to the biotechnology and pharmaceutical industry to advance new technologies from discovery to the ma
provider who helps biotechnology and electronic companies build reliable chemical supply chains that meet their compliance, risk and opera

ts, devices and research tools in the following categories: · Ultra-sensitive fluorometer/luminometer platforms for testing of proteins, bacter
of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagno
mpany that has developed and is now selling an innovative proteomics product line that provides drug companies and life scientists with a dig
nded in the spring of 2003 to bring innovative blood diagnostic products to the market for fatal brain diseases. These diseases are correlated
including storage
o Otsuka founded the original Otsuka Factory in Tokushima, Japan. In 1964, Otsuka Pharmaceutical Co, Ltd. (OPC) was established to enh

ogy by offering Genomics, Proteomics and Glycomics solutions in the form of: (1) Microarray Bio-Chip Services such as Microarray Printing,

organized in 2007 to address the research and validation needs in the human and animal biotech industry. The company uses the Illumina

biopharmaceutical company focused on the discovery, development, production and marketing of pharmaceuticals for the treatment of infla

otechnology company developing new chemical entities for unmet medical needs serving large, rapidly growing markets. Amulet lowers dev
hnology company focused on the development of new, targeted treatments for severe pain. Arcion has a pipeline of products being develop
companies by providing access to a scientific staff, an AAALAC accredited vivarium, and proprietary animal models. Through our affordable

the Biomedical Sciences in Rockville, Maryland, the Red Cross biomedical R&D program investigates transfusion-transmissible infections a

ology company developing products based on novel gene therapy platforms under the SmartVector (TM) trade name. Potential products inc

o support the research, development, and commercialization of enhanced hemostatic technologies, encompassing a broad range of produc

molecular breast imaging. We are now engaged in cooperative projects with local and international academic groups, focused on high reso

clinical trials management organization with a specialized focus on the development of cardiovascular and metabolic drugs and devices. Th

partnering with Pharmaceutical, Biotechnology and Medical Devices firms to design

rch organization (CRO) located in the heart of the I-270 Technology Corridor in Rockville, Maryland. Since 1994 DPC, a minority-owned bus

ation formed exclusively to develop novel biopharmaceutical candidates derived from the secretoglobin family of proteins, initially targeting i

old as a targeted drug/gene delivery system. The safe, effective delivery of TNF bound to colloidal gold for cancer treatment demonstrates th

lth supports the mission of the Natioanl Institutes of Health, the premier research organization in the world and the steward of our nation's in

logy (CARB) is a research center of the University of Maryland Biotechnology Institute (UMBI). CARB is staffed by collaborating scientists fr
biopharmaceutical company focused on the development and commercialization of therapeutics and diagnostics for diseases with substant

on developing and commercializing human neural stem cell technology in the field of regenerative medicine. Co. focuses primarily on the fi

tical company with repositioned drugs in clinical development for the treatment of pain and neurodegenerative diseases. The Company is lis

development company whose purpose is the development of small receptor active peptides for the treatment of HIV/AIDS, development of

otechnology companies, and government and academic institutions with high quality, purified Protein PotentialTM recombinant proteins and

elop and commercialize discoveries made for the pre- and post-exposure treatment for nerve agent exposure and the treatment, diagnosis,

to patients, new medical options for physicians and rewarding careers to employees. With approximately 3,000 employees worldwide, Med

pany with rapidly growing pipeline of product development partnerships in cell-based therapies. The Company’s proprietary, non-viral, ex vi

partnering with Pharmaceutical, Biotechnology and Medical Devices firms to design

es in the field of molecular genetics for the plant breeding industry and has become an internationally recognized leader in the field of DNA m

s senior project managers, physicians, Ph.D. researchers, clinical research associates (CRAs), information technology experts, database an
sease. GenVec uses gene therapy to deliver medically beneficial proteins, such as VEGF, PEDF and TNF-alpha, directly to the site of dise
ELISA, western, Northern and Southern Blot and in Situ analysis.
engineers, cost analysts, data base developers, and graphic, publications, and meeting support staff. Business focus is support to biomedi

dwide. We offer mutation detection, genotyping, carrier detection and prenatal diagnosis in ov er 130 diseases. GeneDx specializes in trans

seases and bio-terrorism threat agents. We focus on veterinary, domestic preparedness, clinical, a ntibody and ELISA products.
ir associated complications.
nd inflammatory diseases. EntreMed�s drug candidates target disease cells and the blood vessels that nourish them. The company�

plications include breeding, immunological and/or disease applications.

d commercializes immunobiotics, consisting of vaccines and therapeutics that assist the body�s immune system to prevent or tr

-IV trials, bioanalytical and QC testing. With over 1,300 employees and 2,000 trials perfor med, SGS serves the pharmaceutical, biotechno
and private institutions.
g: Influenza, HIV, Ebola, and Hemorrhagic fever.
anufactures the hybridization ovens for Affymetrix as well as small accessory products for resea rch. ATR is the US distributor for Infors AG
y's lead product development effort is a tiny implantable glucose sensor for diabetics.
Global headquarters are located in Paris, France and U.S. headquarters are in Bridgewater, NJ. Sa nofi-aventis U.S. employs approximatel
g pharma, biotech and diagnostic firms collaborate with BioServe to identify and validate ma rkers that cause disease while correlating clini
nd biotechnology companies efficiently and expeditiously navigate the regulatory approval process in order to bring new drugs, biologics, a
ng tools and NIST traceable calibration services.

cations. The current offering is the AutoloGel(tm) System, a process that utilizes an autologous platelet gel composed of multiple growth fa

omarker discovery is based on a proprietary technology platform (Gemini) which enables rapid, comprehensive, and quantitative protein pr

e all phases of animal research, transgen breeding, and custom antibody production.
seases. ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The
le cell culture and large-scale transfections) to the drug discovery community.

nizational and logistical support for clinical research, including standard operating procedure (SOP ) and protocol development. The "Advant
ality. Theranostics is the ability to use a diagnostic biomarker(s) for selecting and tailoring t herapy. THX is focusing on oncology, diabetes, i
oad range of process development and manufacturing services to customers and partners seeking to bring promising therapeutics, vaccin
ng of laboratory animals as well as a variety of environmental control systems.
ration of diagnostic devices, novel drugs for human diseases and other bio-products for research, d rug development, and other medical ap

reparedness. The company is also pursuing development of a next generation protein manufacturing tec hnology with specific advantages
s from discovery to the marketplace. Summit is located in Rockville, Maryland, in close proximity to the Food and Drug Administration (FDA
ompliance, risk and operational goals. We supply brand name chemicals from a worldwide network of quality manufacturers and complem

testing of proteins, bacteria, viruses, cells, DNA, etc. · Immunoassays combined with PCR to d etect pathogens in food, water and the env
gnostic and clinical diagnostic tests. The company has applied its proprietary software and sampl e preparation technologies to a wide rang
and life scientists with a digital "snapshot" of the protein signaling pathways in disease samples. The proteomic snapshot allows drug therap
 se diseases are correlated to changes in proteins that aggregate and deposit in brain tissue, a process known as amyloidogenesis. Over t

PC) was established to enhance Otsuka's pharmaceutical product development and commercialization. The company has since grown and

uch as Microarray Printing, High Throughput Immunological or Gene Expression Assays and other Molec ular Biology Services; (2) Cell Cult

ompany uses the Illumina microarray platform to provide SNP genotyping, LOH and CNV studies, and gene expression analyses as well as

ls for the treatment of inflammatory and immune-related diseases.

arkets. Amulet lowers development risk and improves drug safety through our proprietary NORTECH™ te chnology, which integrates Nitric
of products being developed for the treatment of painful diabetic neuropathy, post-herpetic neu ralgia and other forms of moderate and sev
s. Through our affordable cost structure we address the steps in the path from bench to bedside be ginning with the research models throu

-transmissible infections and facilitates improvements in blood collection, processing, and provisio n. The program's researchers include int

me. Potential products include therapeutic treatments and vaccines for a variety of diseases

g a broad range of products with the ability to control bleeding. STB, Inc. is currently focused on th e development and commercialization o

ups, focused on high resolution MRI and molecular imaging.

bolic drugs and devices. The staff of GRS has been serving the sponsors of Phase I-IV research fo r over 20 years. Headquartered in Rockv

PC, a minority-owned business, has been serving pharmaceutical, biotechnology and medical dev ice clients and providing clients with proj

roteins, initially targeting inflammatory and immune diseases. More specifically, the company wi ll advance the clinical development of its le

treatment demonstrates the utility of this delivery system.

e steward of our nation's investment in medical discovery. The Foundation for NIH creates p ublic-private partnerships to seek solutions for

y collaborating scientists from UMBI, the National Institute of Standards and Technology (NIST) and UMBI's Center for Biosystems Researc
or diseases with substantial, unmet clinical needs. The company's product development strategy is b ased on novel therapeutic agents and

focuses primarily on the field of Cell Therapy, which involves the development and commercializatio n of treatments based on transplanting

eases. The Company is listed on the Australian Securities Exchange (ASX) as "QRX", and is headquar tered in Sydney, Australia. Clinical t

HIV/AIDS, development of an HIV vaccine, and the creation of novel anti-inflammatory peptides usefu l in the treatment of chronic inflamma

recombinant proteins and DNA plasmids for research and development. Protein Potential also provi des production clone generation; ferm

the treatment, diagnosis, and control of global infectious diseases of which HIV is the initial tar get.

mployees worldwide, MedImmune is dedicated to advancing science and medicine to help people live better lives and is wholly owned by A

roprietary, non-viral, ex vivo cell loading technology overcomes critical obstacles such as safe ty, scalability and reproducibility which are fu

eader in the field of DNA marker technology. The company has built a broad technology, SNPWave, a multiplexed SNP detection system.

ology experts, database and web designers, statistical programmers, data managers, pharmacolog ists, and research assistants.
 directly to the site of disease. GenVec has an advanced drug discovery engine that enables the rapid discovery, testing and development

ocus is support to biomedical product development, specially FDA regulatory affairs regulatory submittals and Good Manufacturing Practices

GeneDx specializes in translating new genetic tests from the research laboratory to the medical community.

LISA products.

sh them. The company�s goal is to develop and commercialize therapeutic products based on its scientific expertise in angiogenesis, c

une system to prevent or treat disease. The company�s biodefense business focuses on immunobiotics for use against biologica

pharmaceutical, biotechnology and medical device industries. SGS' state of the art facilities include: three Phase I units with a total of 162 be

US distributor for Infors AG in Switzerland and manufactures the unique stackable cabinet shakers for growth of bacteria, yeast, insect cells,

.S. employs approximately 16,000 employees, with 8,000 sales professionals. The U.S. headquarters are in Bridgewater, NJ. Sanofi-aventis
ease while correlating clinical and molecular data to develop new diagnostic tests promoting wellness around the world. BioServe offers the
ng new drugs, biologics, and medical devices to market.

posed of multiple growth factors, other platelet releasates, and fibrin matrix. Additional information regarding Cytomedix is available at: http:/

and quantitative protein profiling from limited microdissected tissue specimens. The company engages in discovery and developmen partner

n alternative splicing. The Company is already generating revenues from a new generation of microarrays. “SpliceArrayTM”, that enable life

development. The "Advantage Suite" software family for clinical data collection and management provides our clients with a framework to ra
g on oncology, diabetes, inflammation, obesity, cardiovascular disease and infectious disease indications.
mising therapeutics, vaccines, and diagnostics to the commercial markets. In addition, BioFactura is utilizing its extensive experience to deve

ment, and other medical applications. AscentGene is affiliated with the Technology Advanced Program (TAP) at the University of Maryland at

with specific advantages in emergency preparedness. Finally, we are also pursuing a treatment for bladder cancer.
Drug Administration (FDA). Summit services span all areas of drug, biologics and device development including preclinical, manufacturing,
nufacturers and complement these products with in-house services such as specialty sourcing, lot control, onsite sampling, temperature-con

in food, water and the environment such as E. coli, Salmonella, anthrax spores, etc. · Antimortem test for Prion Disease · Diagnostic test f
echnologies to a wide range of high throughput bioassay platforms, including mass spectrometry, nuclear magnetic resonance spectrometry
napshot allows drug therapies to be disigned and ultimately personalized to patients based on the protein profiles of the diseases.
s amyloidogenesis. Over time, the deposition of amyloids results in loss of neural cells and brain tissue, and associated symptoms including

pany has since grown and diversified, investing in local enterprises and establishing corporations in 17 countries and regions around the wo

ogy Services; (2) Cell Culture; and (3) Bio-Repository Services.

ession analyses as well as experimental design consultation and data analysis services. Our scientists are experienced in developing custo

gy, which integrates Nitric Oxide donors into FDA approved, ommercially successful therapeutics with known safety and efficacy profiles. Ou
orms of moderate and severe pain. The company is located in Baltimore, Maryland.
he research models through development activities and ultimately commercialization. The company offers a wide range of in-house researc

m's researchers include internationally respected experts in transfusion technology, transfusion-transmitted diseases, and blood component

nt and commercialization of novel FAST dressing products designed to arrest severe hemorrhages. The widespread medical applications of

s. Headquartered in Rockville, Maryland, GRS is a founding member of the Association of Clinical Research Organization (ACRO) and oper

providing clients with project management, monitoring, data management, data analysis, quality assurance and regulatory for Phase I – IV

nical development of its lead candidate, called Claragen, in respiratory disease. The company will take Claragen through Phase 2a and 2b c

ships to seek solutions for cancer, heart disease, Alzheimer's, diabetes, depresstion and other illnesses, as well as help to develop, improve

er for Biosystems Research (CBR) with aim of integrating information from molecular and biological research on complex biological systems
vel therapeutic agents and approaches for cancer diagnosis and treatment, as well as acute and chronic neurodegenerative conditions, suc

nts based on transplanting human neural stem cells.

ydney, Australia. Clinical trials are being conducted in the US, with offices in Rockville, MD.

tment of chronic inflammatory and degenerative diseases for which few or no effective treatments exist.

on clone generation; fermentation optimization and process development; development of analytical assays; development of bulk and drug

and is wholly owned by AstraZeneca, plc (LSE: AZN.L, NYSE: AZN). MedImmune's initial success was driven by the introduction of two ge

eproducibility which are fundamental to commercializing successful cell-based therapeutic programs in oncology, pulmonary, metabolic and

ed SNP detection system. cDNA AFLP, a robust high-throughput gene transcript profiling technology CRoPS, a high throughput SNP indenti

arch assistants.
 testing and development of new product candidates. GenVec has an exciting product portfolio, which includes TNFeradeÃ�ï for the treat

od Manufacturing Practices.

pertise in angiogenesis, cell cycle regulation and inflammation�processes that are vital to the progression of cancer and other diseases

cs for use against biological agents that are potential weapons of bioterrorism and biowarfare. Its marketed product, BioThrax�® (Anthr

units with a total of 162 beds, four bioanalytical labs, and Phase II-IV clinical trial management offices across Europ e, North America & As

acteria, yeast, insect cells, and mammalian cells. ATR promotes the Infors line of fermenters in the US. ATR Biotech, our CA co mpany is lo

ewater, NJ. Sanofi-aventis' R&D organization is comprised of approximately 17,500 scientists working in over 28 research centers aro und
world. BioServe offers the Global Repository(r), a growing library of over 600,000 human DNA, tissue and serum samples link ed to detailed

medix is available at: http://www.cytomedix.com.

y and developmen partnerships with pharmaceutical and biotechnology companies, and outlicensing of novel drug targets and diagno stic m

ArrayTM”, that enable life science researchers to detect crucial disease-associated information. These products are marketed wor ldwide in

nts with a framework to rapidly define and delploy clinical trials worldwide over the Internet. Working with us represents the cu lmination of o

ensive experience to develop technologies that will add value to biopharmaceuticals as they move from discovery through the c linic and int

e University of Maryland at College Park.

preclinical, manufacturing, regulatory, medical writing, and clinical development activities. The primary goal of Summit is to understan d you
sampling, temperature-controlled storage, chemical management and risk mitigation planning. The company has four locations on the east

Disease · Diagnostic test for aggressive versus indolent chronic lymphocytic leukemia (CLL) · Immunoassay combined with enzymat ic ass
c resonance spectrometry, nucleic acid arrays, and immunoassays. Correlogic's technologies have a wide range of applications for t he cre
of the diseases.
ciated symptoms including dementia, motor dysfunction, and other fatal symptoms. Amyloid formation and protein build up in tissues is acc

and regions around the world. These comprise the Otsuka Pharmaceutical Group, a collection of 99 companies employing more than 31,000

enced in developing custom molecular assays for clients using either microarray or multiplex PCR configurations. The company also provide

ty and efficacy profiles. Our focus is on unmet needs in large markets where the pivotal signaling molecule, Nitric Oxide (NO), offers a di ffe

range of in-house research models but also develops customized, innovative models to address unique research requirements. BIOMERE

es, and blood component biology.

ad medical applications of the Company's dressing products will dramatically reduce fatalities caused by blood loss resulting from trauma , s

nization (ACRO) and operates additional offices in Canada, China, Germany and Poland.

egulatory for Phase I – IV clinical trials. DPC has built a strong reputation for high standards of quality, data integrity, cost- effectiveness an

hrough Phase 2a and 2b clinical trials to demonstrate efficacy in patients with chronic nasal rhinitis, sinusitis, and nasal polyposis, a signific

s help to develop, improve and deliver life-saving vaccines.

omplex biological systems. Our facilities are located on the recently expanded (UMBI) Shady Grove campus of the University System of M
generative conditions, such as hypoxia-induced neurological insult, Parkinson's Disease, and Alzheimer's disease. Panacea has an extensi

lopment of bulk and drug product lot release assays; including potency, immunogenicity and antigenicity; studies of the immunogenicity of

the introduction of two generations of antibodies to prevent respiratory syncytial virus (RSV). The first was RespiGam�® (respiratory s

pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current cli nical programs

gh throughput SNP indentification technology that can be applied in any organism without prior sequence knowledge and a large portfolio o
NFeradeÃ�ï for the treatment of cancer and BIOBYPASSÃ��ï¿® angiogen for the treatment of cardiovascular disease. GenVec

cancer and other diseases. Additional information about EntreMed is available on the Company's website at www.entremed.com and in vari

ct, BioThrax�® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention

op e, North America & Asia. With innovative study designs, optimal facilities and strong regulatory intelligence, SGS can significantly improv

ch, our CA co mpany is located in Fremont and supports customers with sales and service.

research centers aro und the world. Sanofi-aventis' current portfolio includes over 50 compounds. Sanofi-aventis has 7 major therapeutic ar
amples link ed to detailed clinical and demographic data from 140,000 consented and anonymized patients from four continents. Leveragin

g targets and diagno stic markers developed through discovery partnerships with leading clinical researchers.

re marketed wor ldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMer

sents the cu lmination of over 25 years of experience and expertise designing, developing and implementing projects serving commercial, g

through the c linic and into the marketplace.

mmit is to understan d you r drug development needs and provide you with the levels of assistance you require to accomplish your goals and
our locations on the east coast, including Jessup, Maryland; Richmond, Virginia; Durham, North Carolina; and Tampa, Florida. Our service

bined with enzymat ic assay to detect botulinum toxin. · High-aspect-ratio microfabrication of metal and composites. Applications include x
of applications for t he creation of disease classification models, biomarker discovery, and new drug discovery, drug response monitoring, b
 build up in tissues is accociated with human diseases such as Creutzfeldt-Jakob disease (CJD), Alzheimer's, and Parkinson Disease. The

mploying more than 31,000 peop le. In 1985, Otsuka established its first healthcare-related business in the U.S., in the Shady Grove Life Sc

The company also provides genetic characterization and pathogen testing services of tissue samples and cell lines. The laboratory is locate

Oxide (NO), offers a di fferentiating clinical advantage that can be backed up by strong composition-of-matter claims in our intellectual prop

requirements. BIOMERE p rovides guidance with government submissions, leases research space at its facility, and conducts research an

s resulting from trauma , surgery or pathologic conditions.

ity, cost- effectiveness and client satisfaction.

nasal polyposis, a significant value-driving milestone. The company will operate in virtual mode, utilizing consultants and contract research

e University System of Maryland.

. Panacea has an extensi ve patent portfolio covering its neurodegenerative and oncology technologies.

of the immunogenicity of vaccine candidates; documentation; and the technologicial know-how to transition therapeutic, vaccine, and diagn

Gam�® (respiratory syncytial virus immune globulin intravenous (human)), a polyclonal antibody introduced in 1996, followed in 1998 b

Current cli nical programs with MaxCyte-engineered cells include: a phase I/II clinical study for treatment of chronic lymphocytic leukemia (C

ge and a large portfolio of software applications supporting the technologies and applications. Keygene exploits its proprietary technologies
vascular disease. GenVec leverages its corporate partnerships to develop product candidates, expand its technology and reduce risk. GenV

.entremed.com and in various filings with the Securities and Exchange Commission.

stration for the prevention of anthrax infection. The company�s commercial business focuses on immunobiotics for use against

GS can significantly improve client's drug development timelines and decision-making processes.

has 7 major therapeutic areas: Cardiology, Thrombosis, Oncology, Internal Medicine, Metabolic disorders, diseases of the Central Nervous
our continents. Leveraging BioServe's robust genomic analytical services, technology, Global Repository and CLIA-certified laboratory, coll

collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improv

ects serving commercial, government, academic, and non-profit research institutions dedicated to advancing understanding of disease proce

accomplish your goals and meet project milestones. Summit can assist your organization by “filling in the gaps” in managing and conducting
ampa, Florida. Our service centers are GMP-compliant and operate under proven ISO 9001: 2000 procedures.

tes. Applications include x-ray anti-scatter grids, nuclear collimators, high-density cell culture plates, etc.
ug response monitoring, bio-security and other applications has been published in 12 peer-reviewed journals.
d Parkinson Disease. These debilitating diseases affect millions of people, with high mortality and significant costs of healthcare delivery. Th

n the Shady Grove Life Sciences Center in Montgomery County, Maryland. As the business grew, it added clinical research to its R&D capa

es. The laboratory is located in Fairfax, Virginia just outside Washington, DC.

ms in our intellectual property portfolio. Our initial focus is to address the unmet medical need of gastroparesis, where there is no effective tr

and conducts research and development activities for clients. Internal programs at BIOMERE LLC include the development of vaccines and

ants and contract research organizations as needed, and maintaining a small staff and office in Rockville, MD, through completion of this mil
peutic, vaccine, and diagnostic proteins and DNA plasmids to large scale cGMP manufacture.

n 1996, followed in 1998 by Synagis�® (palivizumab), a monoclonal antibody. A third-generation antibody is now in clinical testing that

c lymphocytic leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertens

ts proprietary technologies, databases and know-how through comtract research and products for applications in the Life Sciences industry
ogy and reduce risk. GenVec intends to become a fully integrated pharmaceutical company that will develop and commercialize products. P

unobiotics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public he

es of the Central Nervous System and Vaccines.

A-certified laboratory, collaborators gain a co mplete, highly efficient platform for processing diagnostic test results and identifying genomic

d play a key role in improving the treatment of breast cancer and other major cancers. In parallel, ExonHit is developing its own therapeutic

rstanding of disease processes and potential th erapies.

managing and conducting preclinical, manufacturin g, regulatory and/or clinical aspects of your development programs, thus becoming an e
s of healthcare delivery. There are also i mportant animal diseases mitigated mitigated by amyloid formation including Bovine Spongiform E

research to its R&D capabilities, and in 1989, when the comme rcialization phase for products began, was incorporated as Otsuka America

here there is no effective treatment for up to 5 Million sufferers in the US. The goal is to complete a Phase I Clinical study by mid-2009. We

elopment of vaccines and therapeutic agents for a range of di seases including Type 1 and Type 2 diabetes and diabetic complications incl

ugh completion of this mileston e.

now in clinical testing that may have the potential to further improve upon the profile established by Synagis in helping to prevent hospitaliza

monary Arterial Hypertension (PAH). In a ddiction, there are advanced preclinical programs in oncology and regenerative medicine. More th

he Life Sciences industry and more specifically in inn ovative breeding applications such as Breeding by Design.
commercialize products. Powered by an advanced drug discovery approach, GenVec can create new product candidates using its proprieta

or underserved public health needs.

s and identifying genomic markers for powerful new assays. BioServe has headquarters in Beltsville, MD and Hyderabad, India. For more in

loping its own therapeutic pipeline in the field of neurodegenerative disease and cancer. The Company has advanced drug candidates into

grams, thus becoming an extension of your project team. Summit staff has extensive experience in drug development in the pharma/biotech
ding Bovine Spongiform Encephalopathy (BSE, or Mad Cow disease), sheep scrapie, and chronic wasting disease (CWD) in deer and elk. O

orated as Otsuka America Pharmaceutical, Inc. (OAPI). OAPI's primary mission is to market and sell Otsuka-discovered and developed com

cal study by mid-2009. We plan to advance potential additional leads in Cardiovascular disease, Gastrointestinal diseases (GI), Osteoarthrit

diabetic complications including retinopathy, neuropathy and CVD. BIOMERE'S models are also widely used in studies for rheumatoid arthri
ping to prevent hospitalizations due to RSV in high-risk infants. In other areas of infectious disease, MedImmune recently received FDA ap

nerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte systems has
ndidates using its proprietary technologies, AdFAST��. GenVec has an extensive intellectual property portfolio including over 380 is

erabad, India. For more information please visit www.bioserve.com or call 3 01-470-3362.

nced drug candidates into clinical trials and is evaluating several promisin g pre-clinical compounds. ExonHit also has a strategic partnershi

ent in the pharma/biotech and contract service industries as well as direct experienc e working within the Food and Drug Administration (FD
e (CWD) in deer and elk. Our inn!

overed and developed compounds, along with other pharmaceutical products and devices in the U.S. that are in parallel with our corporate

iseases (GI), Osteoarthritis (Pain) and Ophthalmology.

udies for rheumatoid arthritis and multiple sclerosis.

recently received FDA approval for the refrigerated formulation of FluMist (Influenza Virus Vaccine Live, Intranasal), the first innovation in f

The MaxCyte systems has an FDA master File in place at the Center for Biologi cs Evaluation and Research (CBER)
rtfolio including over 380 issued, allowed or pending patents covering its product candidates and technology platforms. The Company has a

has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalm

nd Drug Administration (FDA) and the National Institute of Health (NIH). The staff has board capabilities across technology and therapeutic a
parallel with our corporate business objectives. OAPI's product portfolio of marketed products is focused primarily in the areas of cardiovasc
al), the first innovation in flu prevention technology in more than 60 years. MedImmune's biologics pipeline has more than doubled in size to
orms. The Company has also established collaborations with numerous academic institutions and pharmaceutical and biotechnology comp

ical diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit. Foun ded in 1997, ExonHit is headquar

chnology and therapeutic areas ranging from natural products and small molecules to gene therapies. With this broa d experience base, Su
in the areas of cardiovascular and neuroscience treatments. OAPI is also developing products for FDA review in the US, in therap eutic are
ore than doubled in size to contain approxiamtely 100 research projects and more than a dozen clinical product candidates following its acq
 and biotechnology companies, which are an additional source of important technology and know-how. GenVec is a publicly held company

1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The company is listed on Alternext of Eur

oa d experience base, Summit can provide strategic support to your organization in the preparation of comprehensive development plans a
the US, in therap eutic areas including gastrointestinal and antiseptic disease treatments. The name "Otsuka" translates to "major milestone
andidates following its acquisition by AstraZeneca plc in 2007. The company also has a stronger and more diverse discovery engine with ac
s a publicly held company with over 85 employees, headquartered in a 43,000-square-foot research and development facility in Gaithersbu

s listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005

sive development plans as well as the resources to implement these plans.

nslates to "major milestone". And indeed, in its 80 years, Otsuka's people - physicians, scientists, researchers, sales and marketing professi
e discovery engine with access to a wider range of cutting-edge technologies. MedImmune: Advancing science for better health
ment facility in Gaithersburg, Maryland, the hub of the metro DC biotech corridor.
es and marketing professionals, and numerous other employees - have achieved many major milestones in their mutual quest to create eth
or better health
mutual quest to create ethical and effective products to improve health and the quality of life for people around the world. Otsuka - people c
e world. Otsuka - people creating new products for better health worldwide.
NAMES OF COMPANIES ADDRESS
PHONE NUMBER WEBSITE NUMBER OF STAFF
ANNUAL SALES EMAIL
DESCRIPTION OF INDUSTRY
 Industry Name # of Staffs Annual Earnings Address
1300 Piccard Dr
#202, Rockville, MD
Hospital Emergency Medicine Association 53 20850-4697
15005 Shady Grove
Rd., # 310, Rockville,
Gastroenterology Capital Gastroenterology 25 MD 20850-6374
15001 Shady Grove
Reproductive Rd., #400, Rockville,
Endrocrinology Shady Grove Fertility 16 MD 20850-6320
Cardiovascular 15225 Shady Grove
Disease Cardiac Associates 15 Rd, #201
6000 Executive Blvd.,
#300, Rockville, MD
Internal Medicine Physician Associates 18 20852-3803
6000 Executive Blvd.,
#300, Rockville, MD
Urological Surgery Urological Consultants 18 20852-3803
1401 Rockville 2-
1428ike, Rockville MD
Internal Medicine Food & Drug Administration 17 208

1475 Taney Ave

#201, Frederick MD,
Pediatric Pediatric Center of Fredrick 20 21702-5126

10 Center Dr Msc
1881, Bethesda, MD
Psychiatry Critical Care-NTL Inst of Hlth 29 20892-0001
Pediatric 10 Center Dr Msc
Hermatology- 1928, Bethesda, MD
Oncology National Institutes of Health 25 20892-0001
5550 Friendship Blvd,
Chevy Chase, MD
Internal Medicine Physician Associates 18 20815-7256
 Email Phone Website

Allen III, Yorke / Annulis,

Thomas M 301-921-7900

Butler, James A 301-279-2255

Vicki Gerber 301-340-1188

301-670-3000

Goldstein, Elliot R 301-468-8999

Immergut, Mark A 301-468-8999

Niu, Manette T 301-443-1544

Bromberg, David I 301-662-0133

Carter, Melody C 301-496-9320

Helman, Lee 301-402-2592

Schulman, Joel R 301-468-8999